

Supplementary Table 1. Exact p-values for figure 2.

URINE














Adjusted P-value	FE Ca	Oxalate	Uric Acid	Phosphate	Volume	Citrate	Sodium	Magnesium	TmP/GFR	pH	Osmolality	Free Water Clearance
FD15	0.003370	>0.999999	0.056845	0.002058	0.000821	0.810013	>0.999999	0.000048	0.024698	>0.999999	0.079428	0.004040
FD30	0.000140	>0.999999	>0.999999	0.057221	0.000509	0.066749	>0.999999	0.024692	0.000111	>0.999999	0.125996	0.013957
FD60	0.004693	0.754059	0.343394	0.010473	0.097799	0.426127	>0.999999	0.018395	0.006865	>0.999999	0.360883	0.021602
FD120	0.806656	0.342796	>0.999999	0.032661	0.559921	>0.999999	>0.999999	0.016368	0.000555	>0.999999	0.860033	0.213379
FD180	>0.999999	0.017162	0.026069	0.000329	0.514957	>0.999999	>0.999999	0.027750	0.001692	>0.999999	0.236701	0.037563
R+0	>0.999999	>0.999999	0.015445	0.000002	0.505191	>0.999999	0.000568	0.007798	0.000711	>0.999999	>0.999999	>0.999999
R+1		>0.999999								0.019312		
R+30	>0.999999	>0.999999	>0.999999	>0.999999	0.866086	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999
R+31		>0.999999								>0.999999		
ANOVA summary	<0.0001	0.001424	<0.000001	<0.000001	0.001594	0.014056	0.000034	<0.000001	0.000011	0.012060	0.008156	0.000023


BLOOD












Adjusted P-value	1,25-Dihydroxyvitamin D3	PTH	FGF-23	Renin	Aldosterone	Atrial Natriuretic Peptide
FD15	>0.999999	0.015767	>0.999999	0.011353	>0.999999	0.033014
FD30	0.013625	0.006488	>0.999999	0.002332	0.881279	0.003087
FD60	0.528434	0.133337	>0.999999	0.036261	>0.999999	0.003087
FD120	0.319539	0.822117	>0.999999	0.008913	>0.999999	0.000194
FD180	>0.999999	>0.999999	>0.999999	0.006545	>0.999999	0.015679
R+0	0.000028	>0.999999	0.198271	>0.999999	>0.999999	>0.999999
R+1	>0.999999					
R+30		<0.000001	>0.999999	>0.999999	>0.999999	>0.999999
ANOVA summary	<0.000001	<0.000001	0.075601	0.000181	0.207730	<0.000001

Supplementary Figure 1: Human plasma and urine physiological measurements

a, Urinary and **b**, plasma physiological measurements from NASA astronauts (n=66) exposed to spaceflight up to 180 days and **c**, plasma physiological measurements from Inspiration4 SpaceX astronauts exposed to spaceflight for 3 days. Values were measured pre-flight, during (FD = flight day) and after returning (R). Dashed lines represent upper and lower normal clinical values, or upper limit where only a single line is present. Data are presented as mean \pm SD. Boxed P-values report the repeated measure one-way ANOVA result; all timepoints were compared to pre-flight by pairwise multiple comparison Bonferroni corrected post-hoc tests (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). FE; fraction excretion. TTKG; trans-tubular potassium gradient. Corrected; corrected for albumin. Na; sodium. K; potassium. Mg; magnesium. Cl; chloride. P_{O_4} ; phosphate. H₂O; water. eGFR; estimated glomerular filtration rate corrected for body surface area (BSA). 25-hydroxyvitamin D₃; calcifediol. BUN; blood urea nitrogen.


a**Calcium:Creatinine****FE_{Na}****Potassium****FE_K****TTKG****FE_{Mg}****FE_{Mg} (Corr)****Chloride****FE_{Cl}****FE_{P04}****FE_{H2O}****Creatinine****Specific Gravity**

b

C**Creatinine****eGFR****Blood Urea Nitrogen****BUN:Creatinine****Sodium****Potassium****Calcium (Total)****Chloride****Glucose****Carbon Dioxide****Albumin**

Supplementary Figure 2: Multi-omic DisGeNET over-representation analysis top 100 results by category grouping

The top 100 enriched gene-disease associations are presented for DisGeNET ontological terms relating to **a**, kidney health [kidney; urological; electrolyte; mitochondrial (general); complement; urinary system cancers; blood pressure (renal)], **b**, closely related to kidney injury and disease [Vascular/endothelial; cardiovascular; autonomic dysfunction; diabetes; blood pressure (general)], **c**, general diseases known to impact the kidney [non-urinary systems cancers; aging; inflammation; liver], **d**, no clear connection to the kidney. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.g. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A $\text{Log}_{10}(\text{P-value})$ of 2 was considered significant for ontological term enrichment. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.





C

Omic
Species
Exposure
Sample

Omic
Epiptome
Proteome
Transcriptome
Metagenome
Metabolome
Epigenome

Species
Mouse
Human
Rat


Exposure
Spaceflight
simGCRsim
GCRsim
MGsim

Sample
Kidney
Plasma
Exosome
Faeces

-LogP
4
8
12
16
20




Enrichment
0.14
0.12
0.10
0.08
0.06
0.04
0.02







Supplementary Figure 3: Faecal Microbiome KEGG pathway over-representation analysis results

The top enriched KEGG microbiome pathway ontological terms. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value (no enrichment scores could be calculated). A $\text{Log}_{10}(\text{P-value})$ of 1.3 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Plant-related terms removed from the display.



Supplementary Figure 4: Multi-omic KEGG pathway over-representation analysis top results by category grouping

The top 100 enriched KEGG pathway ontological terms relating to **a**, kidney health or cellular injury/stress, **b**, closely related to kidney injury and disease [vasculature; blood pressure; bone; muscle; diabetes] remodelling, **c**, no clear connection to the kidney, are presented. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.g. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A $\text{Log}_{10}(\text{P-value})$ of 2 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.

a**b****Omic**

Epiproteome
Proteome
Transcriptome
Metagenome
Metabolome
Epigenome

Species



Mouse
Human
Rat

Exposure

Spaceflight
simGCRsim
GCRsim
MGsim

Sample

Kidney
Plasma
Exosome
Faeces

C

hsa05022: Pathways of neurodegeneration - multiple diseases

hsa05020: Prion disease

hsa05208: Chemical carcinogenesis - reactive oxygen species

hsa05200: Pathways in cancer

hsa05012: Parkinson disease

hsa05016: Huntington disease

hsa05165: Human papillomavirus infection

hsa05010: Alzheimer disease

hsa05171: Coronavirus disease - COVID-19

hsa05415: Diabetic cardiomyopathy

hsa04714: Thermogenesis

hsa05132: Salmonella infection

hsa04144: Endocytosis

hsa05205: Proteoglycans in cancer

hsa05014: Amyotrophic lateral sclerosis

hsa01200: Carbon metabolism

hsa04723: Retrograde endocannabinoid signaling

hsa04910: Insulin signaling pathway

hsa03320: PPAR signaling pathway

hsa05163: Human cytomegalovirus infection

hsa05166: Human T-cell leukemia virus 1 infection

hsa04915: Estrogen signaling pathway

hsa05146: Amoebiasis

hsa04974: Protein digestion and absorption

hsa04141: Protein processing in endoplasmic reticulum

hsa04145: Phagosome

hsa05130: Pathogenic Escherichia coli infection

hsa00983: Drug metabolism - other enzymes

hsa05131: Shigellosis

hsa04934: Cushing syndrome

hsa04360: Axon guidance

hsa04932: Non-alcoholic fatty liver disease

hsa01240: Biosynthesis of cofactors

hsa05215: Prostate cancer

hsa05202: Transcriptional misregulation in cancer

hsa05135: Yersinia infection

hsa00280: Valine, leucine and isoleucine degradation

hsa05203: Viral carcinogenesis

hsa05225: Hepatocellular carcinoma

hsa04921: Oxytocin signaling pathway

hsa04922: Glucagon signaling pathway

hsa04142: Lysosome

hsa04713: Circadian entrainment

hsa05416: Viral myocarditis

hsa04927: Cortisol synthesis and secretion

hsa04261: Adrenergic signaling in cardiomyocytes

hsa05120: Epithelial cell signaling in Helicobacter pylori infection

hsa04621: NOD-like receptor signaling pathway

hsa01524: Platinum drug resistance

hsa04918: Thyroid hormone synthesis

hsa03010: Ribosome

hsa05150: Staphylococcus aureus infection

hsa04371: Apelin signaling pathway

hsa04931: Insulin resistance

hsa04670: Leukocyte transendothelial migration

hsa04919: Thyroid hormone signaling pathway

hsa04913: Ovarian steroidogenesis

hsa00650: Butanoate metabolism

hsa05152: Tuberculosis

hsa05231: Choline metabolism in cancer

hsa05207: Chemical carcinogenesis - receptor activation

hsa05134: Legionellosis

hsa05170: Human immunodeficiency virus 1 infection

hsa04666: Fc gamma R-mediated phagocytosis

hsa00590: Arachidonic acid metabolism

hsa05230: Central carbon metabolism in cancer

hsa04146: Peroxisome

hsa00380: Tryptophan metabolism

hsa01212: Fatty acid metabolism

hsa03040: Spliceosome

hsa05204: Chemical carcinogenesis - DNA adducts

hsa00980: Metabolism of xenobiotics by cytochrome P450

hsa04976: Bile secretion

hsa04211: Longevity regulating pathway

hsa05100: Bacterial invasion of epithelial cells

hsa04213: Longevity regulating pathway - multiple species

hsa04080: Neuroactive ligand-receptor interaction

hsa04260: Cardiac muscle contraction

hsa05167: Kaposi sarcoma-associated herpesvirus infection

hsa00030: Pentose phosphate pathway

hsa05110: Vibrio cholerae infection

hsa04935: Growth hormone synthesis, secretion and action

hsa04216: Ferroptosis

hsa00051: Fructose and mannose metabolism

hsa04728: Dopaminergic synapse

hsa04725: Cholinergic synapse

hsa04071: Sphingolipid signaling pathway

hsa05213: Endometrial cancer

hsa01232: Nucleotide metabolism

hsa05214: Glioma

hsa05220: Chronic myeloid leukemia

hsa04657: IL-17 signaling pathway

hsa05164: Influenza A

hsa04973: Carbohydrate digestion and absorption

hsa00071: Fatty acid degradation


hsa05017: Spinocerebellar ataxia

hsa04613: Neutrophil extracellular trap formation

hsa04710: Circadian rhythm


hsa04916: Melanogenesis

hsa05224: Breast cancer




Supplementary Figure 5: Multi-omic Gene Ontology (GO) over-representation analysis top results by category grouping

The top 100 enriched GO ontological terms relating to **a**, biological process, **b**, cellular component **c**, molecular function are presented. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.g. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A $\text{Log}_{10}(\text{P-value})$ of 2 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.


a

b

C

Supplementary Figure 6: qPCR of mitochondrial fission and fusion markers

a, Heatmap of mitochondrial fission and fusion mRNA transcript markers from RR-10 spaceflight-exposed mice (28 days) kidney tissue. **b**, Relative change in the geometric means of all fission or fusion markers. Data are mean \pm 95% CI. A P-value of <0.05 was considered significant. **c**, Stability ranking of reference genes. **d**, Individual normalisation factors by animal. **e**, Mean relative difference in normalisation factor for groups. Data are mean \pm range. A P-value of <0.05 was considered significant. **f**, RNA input vs relative reference gene levels.






Supplementary Figure 7: SPOKE Integrated knowledge network analysis


SPOKE (Scalable Precision Medicine Open Knowledge Environment) was used to integrate the heterogeneous data from several missions, experimental conditions, tissues, species and assay modalities. **a**, SPOKE workflow from inputs through to disease and anatomical associations, via convergent entry nodes for protein, gene, compound and organism nodes. **b**, Meta pathways to kidney disease (red nodes on the far right). Note the abundance of nodes associated with all of the inputting nodes, implying orthogonal confirmation across the inputted 18 -omics datasets of spaceflight conditions and renal pathology.

Supplementary Figure 8: Plasma miRNA Weighted Correlation Network Analysis (WGCNA)


Plasma miRNAs from BNL-1 simGCRsim-exposed mice (~1.5-year dose equivalent) for WGCNA. **a**, Dendrogram grouping miRNAs into three module-eigengenes (ME) according to co-expression profiles. **b**, Comparisons of ME's expression patterns in Sham vs GCR animals. Abundance heatmaps for constituent miRNAs in the ME are given in **c**, ME0, **d**, ME1, **e**, ME2.



C



d

e



Supplementary Figure 9: Kidney miRNA quantitative ISH

BNL-3 simGCRsim-exposed mouse (~1.5-year dose equivalent) kidney sections were stained for **a**, miR-16 and **b**, Let-7a. Data are mean \pm SD. A P-value of <0.05 was considered significant. OSOM; outer stripe of outer medulla. ISOM; inner stripe of outer medulla. IM; Inner medulla. Average; the simple arithmetic mean of the four anatomical regions.


a**miRNA-16****b****miRNA Let-7a**

Supplementary Figure 10: Mouse plasma and urine physiological measurements

a, Urinary and **b**, plasma physiological measurements from NSRL22A GCRsim-exposed mice (~2.5-year dose equivalent). Boxed P-values report the two-way ANOVA treatment group factor result. Data are mean \pm SD. A P-value of <0.05 was considered significant. FE; fraction excretion. Corr; corrected for albumin. Cr; creatinine. K; potassium. Mg; magnesium. Cl; chloride. KIM-1; kidney injury marker-1.

b

□ Male ○ Female



Supplementary Methods

Experimental Design, Considerations and Limitations

For all animal studies, only wildtype and untreated/vehicle control animals were used for data analysis. To maintain consistency and comparability, when studies had serial longitudinal measurements in both control and exposure-treated animals, the control and treatment groups were directly compared rather than comparing the differences from baseline. Where feasible to do so, persons involved in data acquisition or analysis were kept blinded to group identity to minimise the risk of investigator bias.

In the absence of in-flight measurements (L+ or FD+) we chose to look at post-flight (R+) timepoints as close to splashdown as possible to capture spaceflight phenomena with minimal influence from readaptation to microgravity.

Most spaceflight harvested samples would have gone through freeze-thaw cycles, however the quality of data was assessed, and any unsuitable datasets or samples were excluded on this technical basis. Another caveat that should be noted is that kidney that omics from RR-1, RR-3, RR-7, RR-23 animals were performed on different 1/6th portions cut from the kidney. While these portions likely came from the same anatomical region for each omics modality, it is likely that this introduced increased intra-assay variability due to over or under representation of different anatomical regions arising from difficulties in dissecting perfectly reproducible 1/6th portions from the kidney. And as the kidney is relatively heterogeneous organ, it is likely inter-assay comparisons may be confounded by differences in anatomical regions present in different 1/6th portions from the same kidney. All other missions' whole or hemi-sected or hemisected kidneys were processed

under dry-ice/liquid nitrogen to generate a homogenised powder to ensure all anatomical regions were proportionally represented and results from assays could be more accurately compared to one another.

Ethics

All human and animal experiments were approved by institutional animal care and use committees (IACUC/AREC) and human research ethics committees (HREC). In line with the principles of the 3Rs, extant data and tissues were used where possible to reduce the use of additional animals. Human data was anonymised, and group data averages were used where possible to maintain anonymity.

Epigenome

Whole-genome bisulfite sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 ¹	Silveira <i>et al.</i> , 2020 ²	Silveira <i>et al.</i> , 2020 ²
RR-3	Kidney	OSD-163 ³	OSD-163 ³	Silveira <i>et al.</i> , 2020 ²	Silveira <i>et al.</i> , 2020 ²

Transcriptome

Bulk RNA sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 ¹	OSD-102 ¹	OSD-102 ¹
RR-3	Kidney	OSD-163 ³	OSD-163 ³	OSD-163 ³	OSD-163 ³
RR-7	Kidney	OSD-253 ⁴	OSD-253 ⁴	OSD-253 ⁴	OSD-253 ⁴
RR-10	Kidney	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵
RR-23	Kidney	OSD-513 ⁶	OSD-513 ⁶	OSD-513 ⁶	OSD-513 ⁶

MHU-3	Kidney	Suzuki <i>et al.</i> , 2020 ⁷ , OSD-457 ⁸	OSD-457 ⁸	GSE152382 ⁹	See below
MHU-1	Plasma	Shiba <i>et al.</i> , 2017 ¹⁰ , OSD-532 ¹¹	OSD-532 ¹¹	GSE213808 ¹²	GSE213808 ¹² , See below
JAXA	Plasma	OSD-530 ¹³ , Muratani <i>et al.</i> , 2024 ¹⁴	Not available	OSD-530 ¹³ , Muratani <i>et al.</i> , 2024 ¹⁴	OSD-530 ¹³ , Muratani <i>et al.</i> , 2024 ¹⁴ , See below

Differential abundance analysis

MHU-3

Through the Jupyter platform, accessing the Science Managed Cloud Environment (SMCE) database, the default settings were used to generate differential expression analysis, normalization, and volcano plot using the DESeq2 library (v 1.38.3)¹⁵ in R language (v 4.2). Gene annotation for the differential expression analysis was performed with the bioMart library (v 3.16)^{16,17} to access the Ensembl database, searching for mouse-specific genes (mmusculus_gene_ensembl).

MHU-1

Only ground control and microgravity groups were compared for the analysis.

JAXA

Reads in FASTQ files were imported into CLC Genomics Workbench (CLC-GW, ver.10.1.1, Qiagen), mapped to the human (hg19) reference genome, and quantified using a 57,773-gene (human) downloaded from the CLC-GW server to obtain the total count values, which were combined into a table. To plot normalized expression values, total counts were normalized by the scaling option in CLC-GW (normalization value = mean, reference = median mean, trimming 5%). Normalized total count values were log-2 transformed after adding a pseudocount of unity. ANOVAs and Empirical analyses of DGEs with pairwise EDGE test comparisons were performed

in CLC-GW to obtain the fold-change, weighted difference, nominal P-value and FDR-corrected P-value. For the analysis, samples from timepoints L-168d, L-112d and L-56d were pooled and averaged into “pre-flight” for pairwise comparison to either L+5d or L+120d.

Bulk small RNA sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
BNL-1	Plasma	<i>Malkani et al., 2020</i> ¹⁸ . OSD-336 ¹⁹	OSD-336 ¹⁹	<i>Wuu et al., 2020</i> ²⁰	See below

miRNA WGCNA and target pathway analysis

The R package weighted correlation network analysis (WGCNA)²¹ was used to find clusters (ME; module-eigengenes) of highly correlated plasma miRNA transcripts with a high likelihood of co-expression and similar biological function. Dendrograms and heatmaps were generated for all MEs and aggregate differential abundances were calculated for each ME comparing Sham to GCR-exposed animals.

The miRNAs in these MEs were then input into MicroRNA ENrichment TURned NETwork (MIENTURNET²²) webtool to perform TargetScan-based miRNA-target Enrichment analysis using the default settings. This produced a list of mRNAs that were targeted by at least miRNAs within the MEs, and those with a nominal P-value <0.05 underwent DisGeNET²³ or KEGG²⁴ pathway using Metascape²⁵ with default settings. Mouse genes were imported as mouse and analysed as human. This was repeated for miR-125b and miR-16.

Spatial RNA sequencing

10um sections of fresh-frozen axial kidney sections from BNL-1 sham and GCR-exposed mice (n=3 per group) were processed according to the Slide-seqV2 protocol²⁶. Samples were sequenced on an Illumina NovaSeq S2 flow cell 200 cycle kit with a read structure of 43 bases for read 1, 8 bases for the i7 index read and 60 bases for read 2. Each puck received ~340 million reads, corresponding to ~3,400 to ~5,100 reads per bead. Transcripts were then mapped back to bead coordinates and cell type classifications were assigned to each bead (and colour-coded) with the robust cell type decomposition (RCTD) method²⁷ using a pre-existing mouse kidney cell atlas²⁸.

For differential abundance analysis of transcripts per cell type, all beads of a given class were summed from across n=3 pucks per groups, means were then log₂ transformed and DESeq2¹⁵ was used to calculate log-fold change, nominal p-values and adjusted p-values. Those with adjusted p-values <0.05 were listed in **Fig.9D**, and then for each cell type those transcripts with a nominal P-value <0.05 underwent DisGeNET²³ or KEGG²⁴ pathway using Metascape²⁵ with default settings. Mouse genes were imported as mouse and analysed as human.

qPCR

Pre-validated SYBR® green PrimePCR™ primers (Bio-Rad) were used for qPCR analysis of reference genes (*B2m*, *Rps18*, *Tfrc*, *Tbp*, *Ube2d2*), mitochondrial fission markers (*Dnm1l*, *Fis1*, *Mff*) and fusion markers (*Mfn1*, *Mfn2*, *Opa1*) in RNA extracted from RR-10 whole kidney homogenate⁵. Reference gene stability and normalisation factor calculations were done in RefFinder²⁹. Normalised relative abundances were then calculated for each of the fusion and fission markers for RR-10 ground control (n=7) vs spaceflight mice (n=8). To look for relative changes in all markers of fission and fusion, the geometric mean was calculated for both the fission and fusion markers, separately for each animal, and the arithmetic mean of these was then used to compare between groups in GraphPad Prism 9 (v.9.5.1).

The following primers were used:

Gene - assay ID:

Dnm1l - qMmuCID0021702

Fis1 - qMmuCID0020479

Mff - qMmuCID0017784

Mfn1 - qMmuCID0022027

Mfn2 - qMmuCID0023456

Opa1 - qMmuCID0010500

B2m - qMmuCID0040553

Rps18 - qRnoCID0057002

Tbp - qMmuCID0040542

Tfrc - qMmuCID0039655

Ube2d2 - qMmuCID0025334

Proteome

Quantitative fractionated TMT-labelled DDA LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 ¹	Silveira <i>et al.</i> , 2020 ²	Silveira <i>et al.</i> , 2020 ²
RR-3	Kidney	OSD-163 ³	OSD-163 ³	Silveira <i>et al.</i> , 2020 ²	Silveira <i>et al.</i> , 2020 ²
RR-10	Kidney	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵

Data acquisition and processing

Either fresh-frozen whole (BNL-3) or axially hemisected kidneys (NSRL-22A), were homogenised in 1 mL of 1 ml lysis buffer (8M urea, 2M thiourea, Complete protease inhibitor (#1186153001) Phostop protease inhibitor (PHOSS-RO, both Merck)) using the Precellys 24

Tissue homogeniser (6500 rpm, 1x 15 secs) with Lysing Matrix beads (#6913100, MPI Bio). After centrifugation at 15,000 rpm for 5 mins to pellet cellular debris, supernatant was removed and stored at -80°C. 0.5 mL of guanidine hydrochloride buffer (4M GuHCl, 50mM sodium acetate, 25 mM EDTA in ddH₂O, pH 5.8) was added to the pellet with a metal bead (#69989, 5mm, Qiagen) and vortexed at 1300 rpm for 1 hr at room temperature. Once the metal bead was removed, 1.5 ml of ice-cold ethanol was added to the supernatant, vortexed and incubated at -20°C overnight. Precipitates were pelleted at 15,000 rpm for 5 mins, and the ethanol was carefully removed, before drying in a SpeedVac. The original supernatant was then thawed and combined with the dried precipitated pellet material, vortexed well to solubilise and centrifuged again at 15,000 rpm for 5 mins. Protein concentration was quantified with a Bradford assay.

In-solution reduction, alkylation and digestion with trypsin was performed according to a routine digestion protocol prior to subsequent analysis by mass spectrometry. Cysteine residues were reduced with dithiothreitol and derivatised by treatment with iodoacetamide to form stable carbamidomethyl derivatives. Trypsin digestion was carried out overnight at room temperature after initial incubation at 37°C for 2 hours. The digested samples were cleaned up with PR-C18 resins. The cleaned peptide samples were resuspended in loading buffer for LC-MS/MS analysis.

For TMT labelling the cleaned peptide samples were resuspended in 100mM TEAB and labelled with *TMTpro* tags based on the user guide protocol. TMT tag labelling efficiency check showed >99%, and all 16plex tags were combined as one TMTpro set. Three TMTpro sets were generated, with a master pooled reference standard labelled with the 134N tag, allowing up to 45 experimental samples to be investigated that were randomised across the tags and sets (but allowing for equal proportions of each group per set).

In order to explore deeper into the proteome, a fractionation of TMTpro labelled peptide mix prior to LCMS analysis was performed using a high pH reversed phase HPLC. We used an Ultimate 3000 HPLC equipped with a degasser and a UV detector. Mobile phase A was 0.1%

triethylamine (aq), Mobile phase B was 0.1% triethylamine in acetonitrile. Peptides were subjected to a ZORBAX 300Extend-C18 column (4.6 mm inner diameter x 150 mm length, 3.5 μm particle size, part no. 763973-902, Agilent Technologies) and eluted out in a 20-min long two-step linear gradient from 0% to 50% for 9 min and from 50% to 90% buffer B for 1 min and keeping 90% buffer B for another 1 min, at a flow rate of 0.4 ml/min. The peptide mixture was fractionated into a total of 16 fractions, which were consolidated into 8 super-fractions. Peptide fractions were dried using a vacuum centrifuge and resuspended in 2% acetonitrile, 0.05% TFA (aq).

Chromatographic separation was performed using an Ultimate 3000 NanoLC system (ThermoFisherScientific, UK). Peptides were resolved by reversed phase chromatography on a 75 μm *50cm C18 column using a three-step gradient of water in 0.1% formic acid (A) and 80% acetonitrile in 0.1% formic acid (B). The gradient was delivered to elute the peptides at a flow rate of 250 nl/min over 120 min. The eluate was ionised by electrospray ionisation using an Orbitrap Fusion Lumos (ThermoFisherScientific, UK) operating under Xcalibur v4.4. The instrument was programmed to acquire MS data using "Synchronous Precursor Selection with Multi-notch MS3" method (SPS MS3) by defining a 3s cycle time among a full MS scan, MS/MS fragmentation and MS3 fragmentation. We acquired one full-scan MS spectrum at a resolution of 120,000 at 200 m/z with 100% normalized AGC target and a scan range of 400~1500m/z and maximum injection time 100 ms. The MS/MS fragmentation was conducted using collision-induced dissociation (CID) and quadrupole ion trap analyzer. Parameters were set up as 100% normalized AGC target, NCE (normalized collision energy) 35, q-value 0.25, isolation window 1.2 Th and maximum injection time 50 ms. The MS3 scan was analyzed using higher-energy collision dissociation (HCD) and Orbitrap analyzer with a synchronous precursor selection. Parameters included number of SPS 10, NCE 65, 400% normalized AGC target, maximum injection time 105 ms, resolution 50,000 at 200 Th, isolation window 1.6. 2-6 charged states were defined within this method.

Raw mass spectrometry data were processed into peak list files using Proteome Discoverer (ThermoScientific; v2.5) (PD 2.4). Processed data was then searched using Sequest search

engine embedded in PD 2.5, against the current version of the reviewed Swissprot *Mouse* database downloaded from Uniprot³⁰. The following parameters were used:

Spectrum Selector

Min. Precursor mass: 350 Da
 Max. Precursor mass: 10000 Da
 S/N Threshold (FT-only):1.5

Mascot/Sequest

Database: Uniprot
 Enzyme: Trypsin
 Missed cleavage: 2
 Precursor mass tol: 10 ppm
 Fragment mass tol: 0.6 Da
 Dynamic modifications:
 Carbamidomethyl (C)
 Oxidation (M)

Peptide validator

Target FDR (strict): 0.01
 Target FDR (relaxed): 0.05

TMT Reporter Quantification

Co-Isolation Threshold.: 50
 SPS Mass Matches[%] Threshold: 50 (65 as default)
 Average Reporter S/N Threshold: 10

Quantitative label-free SEER DIA LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Inspiration4	Plasma	OSD-571 ³¹	By Request	OSD-571 ³¹	OSD-571 ³¹ , See "DAA" below
Inspiration4	Exosome	OSD-571 ³²	By Request	OSD-571 ³²	OSD-571 ³² , See "DAA" below

Plasma Slow Off-Rate Modified Aptamers

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-19	Plasma	<i>Lee et al., 2020</i> ³³ , OSD-342 ³⁴	OSD-342 ³⁴	OSD-342 ³⁴	See "DAA"

Shotgun LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Cosmonauts	Urine	<i>Pastushkova et al., 2013</i> ³⁵	PASS00239 ³⁶	PASS00239 ³⁶	See below

Network Analysis

Cosmonaut (n=10 per timepoint) urinary shotgun proteomes pre-flight were compared with those measured post-flight R+1d and R+7d. Proteins that were absent pre-flight but detected after spaceflight were taken forward for network analysis in Cytoscape StringApp³⁷ using the latest version of the STRING³⁸ database. This was then visualised in Cytoscape using the yFiles Tree layout, excluding singletons.

Differential abundance analysis (DAA)

In-house R scripts were used for proteomics data processing and statistical analysis. The corrected reporter intensity values were used to analyse proteomics data. Protein groups containing matches to decoy database or contaminants were discarded. Total intensity for each reporter were calculated and matched to correct for the sample loads in each experiment. Only proteins that were quantified in the pooled samples were used for the analysis. Subsequently, internal reference scaling (IRS) method was employed to normalize protein intensities between different runs using common proteins in pooled internal standards. The data was log2 transformed and scaled by subtracting the median for each sample. LIMMA was employed to determine differentially abundant proteins between groups.

Inspiration4

For the analysis, samples from timepoints L-92d, L-44d and L-3d were pooled and averaged into “pre-flight” for comparison to immediate post-flight R+1d.

Epiproteome

Quantitative fractionated TMT-labelled DDA LC-MS/MS of phospho-enriched peptides

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-10	Kidney	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵ , See below

Differential abundance analysis

In-house R scripts were used for phosphoproteomics data processing and statistical analysis. Only phosphopeptides with a single modified residue were considered for further analysis. These phosphopeptides were mapped back to genes with the residue amino acid and position annotated. The data was log₂ transformed and LIMMA was employed to determine differentially abundant phosphopeptides between groups. For analyses that required single entries for each gene, the phosphopeptides were collapsed into a single gene and their intensity scores aggregated to obtain a generalised change in the overall phospho-status of the protein encoded by that gene.

Metabolome

Quantitative label-free UHPLC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Inspiration4	Plasma	OSD-571 ³⁹	By Request	OSD-571 ³⁹	OSD-571 ³⁹ , See below
MHU-3	Plasma	<i>Suzuki et al., 2020</i> ⁷ ; <i>Urano et al., 2021</i> ⁴⁰	By Request	ibSLS ⁴¹	See below
CNSA	Serum	<i>Zhang et al., 2020</i> ⁴²	By Request	<i>Zhang et al., 2020</i> ⁴²	<i>Zhang et al., 2020</i> ⁴² , See below

Differential abundance analysis

Inspiration4

For the analysis, samples from timepoints L-92d, L-44d and L-3d were pooled and averaged into “pre-flight” for comparison to immediate post-flight R+1d.

MHU-3

For the analysis, samples from ground control and spaceflight animals were directly compared for timepoints L+18d and R+2d. Data were Log₂ transformed, fold changes were calculated, and nominal p-values and adjusted p-values were determined in GraphPad Prism 8 using the multiple tests option.

Over-representation analysis

Metabolites with a nominal P-value of <0.05 and which had a successful name check were taken forward for KEGG module pathway analysis (targeted) using MetaboAnalyst 5.0⁴³ with the default settings.

Microbiome

Whole metagenome shotgun sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-6	Faeces	OSD-249 ⁴⁴	OSD-249 ⁴⁴	See "DP"	See "DAA"
RR-9	Faeces	OSD-250 ⁴⁵	OSD-250 ⁴⁵	See "DP"	See "DAA"
RR-10	Faeces	OSD-466 ⁴⁶	OSD-465 ⁴⁶	See "DP"	See "DAA"
RR-23	Faeces	OSD-465 ⁴⁷	OSD-465 ⁴⁷	See "DP"	See "DAA"

16S rRNA gene amplicon sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Faeces	<i>Jiang et al., 2019</i> ⁴⁸	OSD-212 ⁴⁹	<i>Jiang et al., 2019</i> ⁴⁸	<i>Jiang et al., 2019</i> ⁴⁸
STS-135	Faeces	<i>Ritchie et al., 2015</i> ⁵⁰	OSD-72 ⁵¹	<i>Ritchie et al., 2015</i> ⁵⁰	<i>Ritchie et al., 2015</i> ⁵⁰

Data processing (DP) and differential abundance analysis (DAA)

Sequence data were processed using the Nephel platform⁵², provided by the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, MD (1). The Whole metaGenome Sequence Assembly pipeline, version 2 (WGSA2), was employed to assess whole-genome shotgun sequencing data. Additionally, pre-processed amplicon sequencing taxa abundance data from RR-1 and STS-135 were obtained from previous publications.

Data analysis was conducted using R (Version 4.2.1). Centred log-ratio transformed abundance values of the observed taxa detected in over 10% of the samples were calculated. Differential abundance between mission-matched Flight and Ground Control groups was evaluated using a linear model, followed by a Benjamini-Hochberg False Discovery Rate correction. Relevant R libraries utilised in this analysis can be found online^{53,54}.

For a comprehensive multi-omics analysis, total microbiome differential abundance results were employed. A kidney stone (KS) relevant microbe list was compiled from existing literature, which

was then used for targeted differential abundance assessment. Directionality, degree, and significance of difference measures between groups for each mission were compiled for comparative purposes.

Physiology

Sample collection and processing

NSRL-22A

Urine collection was performed in awake mice to obtain spontaneous and uncontaminated samples. Mice were gently handled over a sheet of Saran® wrap or Parafilm® to facilitate micturition. Upon collection, each urine sample was carefully divided into two aliquots. One aliquot was immediately acidified with HNO₃ to achieve a final concentration of 1% v/v, preventing precipitation of electrolytes and maintaining sample integrity. Both aliquots were then promptly stored at -80°C to preserve their biochemical constituents until further analysis. For blood collection, mice were subjected to terminal anaesthesia to minimize distress and ensure compliance with ethical guidelines. Blood samples were drawn from the vena cava using a fine needle and syringe. Plasma was separated by transferring the blood into Microvette® CB 300 LH (Sarstedt) tubes and centrifuging at 2000 g for 5 min. The resulting plasma supernatant was carefully aspirated and stored at -80°C for future analysis. Both plasma and non-acidified urine samples were analysed for creatinine levels by employing either the standard Jaffe reaction or the enzymatic method, depending on the investigator's preference and laboratory resources. Electrolyte levels, biochemistries and biomarkers were assessed using the Siemens Dimension RxL Max Integrated Chemistry System, at the Core Biochemical Assay Laboratory at Addenbrooke's Hospital, Cambridge, UK.

Inspiration4

Plasma samples collected from astronauts at timepoints L-92d, L-44d and L-3d were grouped and averaged into “pre-flight” for comparison against individual post-flight timepoints R+1d, R+45d, R+82d and R+194d. These samples were analysed by Quest Diagnostics using the Comprehensive metabolic panel [CMP; CPT code 80053].

NASA

A historical collection of archived astronaut frozen plasma and urine aliquots were collected and stored at -80C over many years. Clinical chemistries, endocrine profiles and biomarkers were obtained at the Nutritional Biochemistry Laboratory at NASA Johnson Space Center. Timepoints L-180d and L-45d were grouped and averaged as “pre-flight” for comparison to individual timepoints L+15d, L+30d, L+60d, L+120d, L+180d, R+0d and R+30d.

Functional calculations

eGFR was calculated using the new 2021 CKD-EPI creatinine (2009 CKD-EPI creatinine fit without race) [new eGFR_{Cr}(AS) equation⁵⁵]. The fractional excretions of electrolytes were determined by (Urine solute x Plasma creatinine) ÷ (Urine creatinine x Plasma solute). A corrected FE_{Mg} was determined, as ~30% of magnesium is protein bound and is not filtered, and therefore the plasma magnesium must be multiplied by 0.7 i.e. $[pCr \times uMg] / [(0.7 \times sMg) \times pCr]$ ⁵⁶. The FE_{H₂O} is the volume of water that appears as urine compared to the amount filtered. Thus, $FE_{H_2O} = V / GFR$. Since $GFR = UC_r \times V / PC_r$, $FE_{H_2O} = V \times PC_r / UC_r \times V$. Simplifying, $FE_{H_2O} = PC_r / UC_r$ (then multiply by 100 to express as a percentage⁵⁷). The ratio of tubular maximum reabsorption of phosphate (TmP) to GFR is used to evaluate renal phosphate transport. TmP/GFR is calculated using the following steps: 1) Calculate the ratio of phosphate clearance to creatinine clearance (CP/CCr) $CP/CCr = \text{serum creatinine} \times \text{Urine phosphate} / \text{Urine creatinine} \times \text{Serum phosphate}$ (This ratio is normally less than 0.15 and is often elevated in primary hyperparathyroidism). 2) Subtract this fraction from 1.0 to give the fractional tubular reabsorption

of phosphate (TRP). $TRP = 1 - \text{serum creatinine} \times \text{Urine phosphate} / \text{Urine creatinine} \times \text{Serum phosphate}$. 3) If TRP is ≤ 0.86 then phosphate reabsorption is maximal and there is a linear relationship between plasma phosphate concentration and excretion and TmP/GFR which is calculated by: $TmP/GFR = TRP \times \text{serum phosphate}$. 4) If TRP is > 0.86 relationship between plasma phosphate concentration and excretion is curvilinear and TmP/GFR is defined as follows: $TmP/GFR = \alpha \times \text{serum phosphate}$, where $\alpha = 0.3 \times TRP - (0.8 \times TRP)^{58}$. The transtubular potassium gradient (TTKG) is used to gauge renal potassium secretion by the cortical collecting duct, indirectly assessing mineralocorticoid bioactivity in patients. $TTKG = U_K/P_K \times P_{Osm}/U_{Osm}^{59}$. Estimated serum osmolality was determined using the Khajuria and Krahn equation: $OSMc = 1.86(Na + K) + 1.15(Glu / 18) + (Urea / 6) + 14^{60}$. Free water clearance is calculated as $C_{H_2O} = V(1 - U_{Osm}/P_{Osm}^{61})$.

Multi-omic integrated pathway over-representation analyses

To integrate datasets from across different omics, species, missions and tissues, all biomolecules (e.g. phosphoproteins, proteins, transcripts and methylated DNA) were linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites) and converted to the human orthologs where necessary. To perform over-representation analysis in Metascape²⁵ using any of the pathway databases, the less stringent nominal p-value of $P < 0.05$ was used to threshold differentially expressed hits within each dataset for analysis (with the exception of RR-23 where the adjusted p-value was used to threshold the number of hits to a manageable number), with a $-\text{Log}_{10}(P\text{-value})$ of 2 being considered significant for ontological term enrichment. This approach reduces the risk of false-negatives due to potentially overly stringent multiple comparison adjustment of the p-value at an individual dataset level, while mitigating the risk of false-positives at the convergence of hits during ontological term enrichment. The degree of confidence in the validity of results can then be drawn from the robustness of replication across orthogonal and/or independent datasets.

DisGeNET²³ analysis was performed using Metascape with default settings. Differentially expressed gene lists (p.value <0.05) from each dataset were imported into Metascape. Mouse genes were imported as mouse and analyzed as human. DisGeNET outputs containing enriched human disease terms (-LogP >2) were downloaded and visualized using Python's seaborn and matplotlib libraries. The circle size represents -LogP values and the circle color represents enrichment ratio.

KEGG pathway analysis²⁴ was performed using Metascape with default settings. Differentially expressed gene lists (p. value < 0.05) from each dataset were imported into Metascape. Mouse genes were imported as mouse and analyzed as human. KEGG outputs containing enriched KEGG pathways (-LogP >2) were downloaded and visualized using Python's seaborn and matplotlib libraries. The circle size represents -LogP values and the circle colour represents enrichment ratio.

Enriched GO⁶² terms were obtained from clusterProfiler outputs. GO enrichments containing biological process ontologies were visualized using Python's seaborn and matplotlib libraries. The circle size represents -LogP values and the circle color represents enrichment ratio.

For analysis of significant genes (p. value < 0.05) that had a consensus in directionality, we only used kidney proteomic and transcriptomic datasets and ranked according to the log₂ fold change direction and the number of times observed across all datasets. The highest ranked upregulated and downregulated genes were plotted using CoMut⁶³.

Integration of multi-omics and physiological data

The Scalable Precision Medicine Open Knowledge Engine (SPOKE)⁶⁴ is a population-level heterogeneous knowledge graph. SPOKE has distilled and connected information from over 40 databases into a structured graph with 21 different node types and 55 edge types. The databases

cover numerous biomedical domains, from basic science to clinical research. Previously, SPOKE was leveraged to analyse GeneLab gene expression data from mice flown in space. Using only data from mice, this study uncovered biological and clinical changes experienced by human astronauts.

Due to the heterogeneous structure of SPOKE, it is possible to harmonise multi-omics datasets. This is achieved by identifying “entry points” for each dataset. Entry points represent the logical overlap between SPOKE nodes and the entity being quantified in the dataset. Here entry points consisted of Gene (transcriptome and epigenome), Protein (proteome and post-translation modification), and Compound (metabolome) nodes. Once the external datasets were connected to SPOKE, Degree Weighted Path Count (DWPC) was used to score the connectivity between each entry node and the nodes in SPOKE. The top 5% of nodes from each entry point were merged into a single graph. The interconnected paths between the entry points provide a system-level view of how space flight impacts the kidneys. The resulting knowledge map figures highlight shared paths that traverse nodes involved in kidney morphogenesis, kidney stones, and chronic kidney disease.

Imaging

Sample fixation and processing

Mouse kidney samples were harvested and fixed through immersion in freshly prepared 4% (w/v) formaldehyde-PBS solution (pH 6.9) for 16 hours at 37°C. Subsequently, the samples were washed three times with PBS with 0.02% Na-Azide and stored at 4°C until they were embedded in paraffin.

Histopathology and Brightfield WSI

2-3 μm FFPE sections from NSRL-22A kidneys were prepared, deparaffinised using Histoclear (National Diagnostics), and rehydrated through a series of graded methanol steps. These were then stained for either Haematoxylin & Eosin (#ab245880, Abcam) or Masson's Trichrome (#ab150686, Abcam) according to the manufacturers guidelines.

Sections underwent brightfield whole slide imaging with 20X objective tiled and stitched focus stacks taken for each section on a Zeiss Axio Scan.Z1 slide scanner. The resultant images were viewed in QuPath (v0.4.3) and semi-quantitatively scored for any histopathological findings.

Immunostaining and Confocal WSI

5 μm FFPE sections from RR-10 kidneys were prepared, deparaffinised using Histoclear (National Diagnostics), and rehydrated through a series of graded methanol steps. Antigen retrieval was performed using [1X] R-Universal buffer (AP0530) in a 2100 antigen retriever for a single heat-pressure cycle (Aptum Biologics). Sections were then permeabilized with 0.05% (v/v) Triton X-100-PBS solution for 20 minutes and incubated with Section Block 'ready-to-use' (AP0471; Aptum Biologics) for 30 mins at RT. Primary antibodies were incubated overnight at 4°C for 16 hours at specified concentrations below, diluted in Antibody Diluent 'FF/PE Sections' (AP0472; Aptum Biologics). For phospho-specific antibodies, 10 $\mu\text{g}/\text{ml}$ of the non-phospho peptide used to raise the antibody was added per 2 $\mu\text{g}/\text{ml}$ of the antibody used. Negative control samples omitted the primary antibody and were processed simultaneously. Following incubation, slides were washed by dipping slides 50x times in 0.05% (v/v) Triton X-100-PBS for 3 rounds, and incubated with secondary antibodies for 1 hour at RT. Pre-absorbed fluorochrome conjugated secondary antibodies were utilised at the concentrations below, diluted in Antibody Diluent 'FF/PE Sections' (AP0472; Aptum Biologics). After washing, slides were mounted using Prolong Gold antifade (#P36930, Life Technologies), permitted to cure for 48-72hrs, sealed with CoverGrip Coverslip Sealant (#23005; Biotium) and protected from light exposure.

Immunofluorescent images were captured using either a Zeiss LSM700 LED laser-scanning confocal microscope or Leica SP8 white-light laser-scanning confocal microscope using 488-nm, 555-nm and 639-nm laser lines, employing a 10X/0.3NA (Zeiss) or 10X/0.5NA (Leica) objective. Zeiss acquisition parameters included single field of view, 8-bit resolution, 1844 x 1844 pixels, 1x digital zoom, 3.85 μ s pixel dwell time, 4-line Kalman filtering, sequential (by line) channel imaging, and a 4-slice z-stack with a 6 μ m thickness to account for chromatic aberration.

Leica acquisition parameters included tile scanning with a 10% overlap, 8-bit resolution, 1024 \times 1024 pixels, 0.75x digital zoom, 600 Hz scan speed, 6-line Kalman filtering, sequential (by line) channel imaging, and a 3-slice z-stack with a 5 μ m thickness to account for chromatic aberration.

Images were processed using FIJI image analysis software (v.1.53p). Fluorescent z-stacks underwent background subtraction (200 px radius rolling ball) and maximum intensity z-projection. Brightness and contrast adjustments were made using linear histogram stretching to enhance visibility.

PRIMARIES

Target: anti-rat total NCC (tNCC) [cross reacts with mouse and human total NCC]

Host species: Rabbit

Clonality: pAb full IgG

Product: Abcam (ab95302)

Lot #: GR3274565-9

Working Concentration: @2 μ g/mL

Validation: Previously published in two models that increase or decrease NCC expression (<https://doi.org/10.1093/hmg/ddv185> and <https://doi.org/10.15252/emmm.201505444>)

Target: anti-human phospho-NCC (pNCC) Thr46, Thr50, Thr55 [cross reacts with mouse pNCC Thr44, Thr48, Thr53]

Host species: Sheep

Clonality: pAb full IgG

Product: MRC PPU Reagents and Services (S908B)

Lot #: 2nd Bleed

Working Concentration: @2ug/mL (+ 10ug/mL non-phosphopeptide to ensure specificity)

Validation: Previously published in model that decreases NCC phosphorylation (<https://doi.org/10.1093/hmg/ddv185>)

Target: anti-human phospho-NCC (pNCC) Thr60 [cross reacts with mouse pNCC Thr58]

Host species: Sheep

Clonality: pAb full IgG

Product: MRC PPU Reagents and Services (S995B)

Lot #: 1st Bleed

Working Concentration: @2ug/mL (+ 10ug/mL non-phosphopeptide to ensure specificity)

Validation: Previously published in model that increase or decreases NCC phosphorylation (<https://doi.org/10.1093/hmg/ddv185> and <https://doi.org/10.15252/emmm.201505444>)

SECONDARIES

Target: Alexa Fluor 647 anti-goat IgG (cross reacts with sheep IgG)

Host species: Donkey

Clonality: pAb IgG Fab Fragment

Product: Jackson ImmunoResearch (711-607-003)

Working Concentration: @8ug/mL

Validation: (lots of citations) <https://www.jacksonimmuno.com/catalog/products/711-607-003>

Target: Alexa Fluor 647+ anti-Goat IgG (cross reacts with sheep IgG)

Host species: Donkey

Clonality: pAb full IgG

Product: ThermoFisher (A32849)

Working Concentration: @10ug/mL

Validation: (lots of citations) <https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32849>

Target: Alexa Fluor 555+ anti-rabbit IgG

Host species: Donkey

Clonality: pAb full IgG

Product: ThermoFisher (A32794)

Working Concentration: @10ug/mL

Validation: (lots of citations) <https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32794>

Target: Alexa Fluor 488 anti-rabbit IgG

Host species: Donkey

Clonality: pAb IgG Fab Fragment

Product: Jackson ImmunoResearch (711-547-003)

Working Concentration: @8ug/mL

Validation: (lots of citations) <https://www.jacksonimmuno.com/catalog/products/711-547-003>

miRNA in situ hybridisation and brightfield WSI

FFPE blocks for BNL-3 kidneys were trimmed to remove tissue exposed to air, and fresh 5µm sections were taken. These were not baked onto the slide and stored with desiccant instead. Samples were then processed using the miRNAscope™ HD RED assay (#324531 and #324500,

ACD-Biotechne) with the FFPE tissue section workflow according to the manufacturers guidelines. miRNAscope™ Probes against the following were used: mmu-miR-125b-5p (#1082311-S1), mmu-let-7a-5p (#727761-S1) and mmu-miR-16-5p (729031-S1).

Sections underwent brightfield whole slide imaging with 20X objective tiled and stitched focus stacks (with extended depth of focus) taken for each section on a Zeiss Axio Scan.Z1 slide scanner. Using QuPath (v0.4.3) the cortex, outer stripe of the outer medulla, inner stripe of the outer medulla and inner medulla were manually annotated with the aid of a Wacom cintiq pro 32 to create a segmentation mask of the anatomical regions for area calculation. Ilastik (v1.4.0)⁶⁵ automated (supervised) pixel-level classification was then trained to identify positive miRNAscope probe staining. A custom in-house python script was then used to count all positive staining and calculate the area of all anatomical regions, so that the density of each miRNA per unit area of each region could be determined for each kidney section.

Optical Clearing and 3D imaging

Tissue transformation, delipidation and refractive index matching

Quartered formaldehyde-fixed kidneys from RR-10 mice were tissue transformed using the SHIELD protocol⁶⁶ and reagents from Lifecanvas technologies (MA, USA) based on (10.1038/nbt.4281). SHIELD-transformed kidneys were delipidated (Lifecanvas Technologies; Full Passive Pipeline Protocol v4.06) for approximately 10–14 days at 37°C in 40 mL of passive delipidation buffer with gentle agitation in EasyClear device. Following delipidation, tissues were washed in several rounds of PBS at 37°C overnight to remove any delipidation buffer. Before imaging tissues were immersed in Incubated in EasyIndex RI 1.53 refractive index matching solution as per protocol. Tissues were then embedded in 2% w/v ultra-low melting point agarose (Sigma A5030) blocks made up with EasyIndex solution to immobilise the samples. These were then stored in EasyIndex in airtight containers shielded from light prior to imaging.

MesoSPIM imaging

Samples were mounted in quartz cuvettes and immersion oil with refractive indices matching that of EasyIndex, and then suspended and aligned for light-sheet fluorescence imaging with a MesoSPIM⁶⁷. Images were captured at 16-bit for 1-channel dual laser lightsheet illumination (488 nm excitations) to obtain autofluorescence emissions at 2048 x 2048 pixels in the XY, with a Z depth range of 700-1200 pixels, giving a pixel resolution of 3.26 μm (XY) and 4.0 μm (Z).

Image analysis

To evaluate any qualitative changes in gross morphology images were imported into Syglass⁶⁸ (v.1.7.2-79; <https://www.syglass.io/>; RRID: SCR_017961) for visual investigation by nephrologists and histopathologists in 3D virtual space using Meta Quest 2 VR headsets. Images were also imported into Imaris⁶⁹(v10.0) for visualisation on a Wacom cintiq pro 32" 4K touchscreen monitor. 3D video renders were later generated with Syglass (v.2.0.0) and Z-slice video created with FIJI (ImageJ; v.1.54h).

Morphometry

Normalised kidney weights

PI and NASA GeneLab records for all animals included in the study were examined for bodyweight and kidney wet weight measurements. Only BNL-1, BNL-2, BNL-3 and RR-23 missions had complete kidney and body weight information available. Where available, the weights of both left and right kidneys were averaged, and the kidney weights were normalised against bodyweight for the same animal and expressed as a percentage. All ground control and

sham animals that received no exposure treatment were grouped into control for pairwise comparisons against GCR (animals that only received either full or simplified galactic cosmic radiation simulations) or MG (animals that only underwent hindlimb unloading microgravity simulation) or GCR + MG (animals that underwent a combination of GCR and MG or were exposed to spaceflight).

Histomorphometry

Whole slide images of tiled immunofluorescent confocal images taken from RR-10 were used for analysis. Using QuPath (v0.4.3) the cortex was manually annotated with the aid of a Wacom Cintiq Pro 32 to create a segmentation mask of the major anatomical regions for area calculation (e.g. cortex vs medulla). Similarly distal convoluted tubules (DCT) labelled with antibodies against total NCC / phospho-NCC, the canonical DCT marker, were annotated. Initially, only a handful of tubules were annotated from each slide, and these were then used to train Ilastik (v1.4.0)⁶⁵ for automated (supervised) pixel-level classification of DCTs. These were then further manually refined to remove/include any false-positive/negatives. A custom in-house python script was then used to compute the number of discrete tubules positive for DCT markers, the corresponding area of each of these as well as the total cortex area, such that average tubule area and DCT density per area of cortex could be determined for each kidney section.

REFERENCES

1. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-102>.

2. Silveira, W. A. da *et al.* Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact. *Cell* **183**, 1185-1201.e20 (2020).
3. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-163>.
4. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-253>.
5. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-462>.
6. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-513>.
7. Suzuki, T. *et al.* Nrf2 contributes to the weight gain of mice during space travel. *Commun. Biol.* **3**, 1–14 (2020).
8. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-457>.
9. GEO Accession viewer.
<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152382>.
10. Shiba, D. *et al.* Development of new experimental platform 'MARS'—Multiple Artificial-gravity Research System—to elucidate the impacts of micro/partial gravity on mice. *Sci. Rep.* **7**, 10837 (2017).
11. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-532>.
12. Masafumi, M. GEO Accession viewer.
<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213808>.
13. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-530>.
14. Masafumi, M. CD36-associated extracellular mitochondria as a hallmark of space response.

15. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
16. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
17. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
18. Malkani, S. *et al.* Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. *Cell Rep.* **33**, 108448 (2020).
19. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-336>.
20. Wu, Y.-R. *et al.* LET-Dependent Low Dose and Synergistic Inhibition of Human Angiogenesis by Charged Particles: Validation of miRNAs that Drive Inhibition. *iScience* **23**, (2020).
21. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* **9**, 559 (2008).
22. Licursi, V., Conte, F., Fiscon, G. & Paci, P. MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis. *BMC Bioinformatics* **20**, 545 (2019).
23. Piñero, J. *et al.* The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Res.* **48**, D845–D855 (2020).
24. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* **28**, 27–30 (2000).
25. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
26. Stickels, R. R. *et al.* Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. *Nat. Biotechnol.* **39**, 313–319 (2021).

27. Cable, D. M. *et al.* Robust decomposition of cell type mixtures in spatial transcriptomics. *Nat. Biotechnol.* **40**, 517–526 (2022).
28. Miao, Z. *et al.* Single cell regulatory landscape of the mouse kidney highlights cellular differentiation programs and disease targets. *Nat. Commun.* **12**, 2277 (2021).
29. Xie, F., Wang, J. & Zhang, B. RefFinder: a web-based tool for comprehensively analyzing and identifying reference genes. *Funct. Integr. Genomics* **23**, 125 (2023).
30. The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic Acids Res.* **51**, D523–D531 (2023).
31. Mason, C. E. Inspiration4 plasma proteomics. (2023).
32. Mason, C. E. Inspiration4 exosome proteomics. (2023).
33. Lee, S.-J. *et al.* Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. *Proc. Natl. Acad. Sci.* **117**, 23942–23951 (2020).
34. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-342>.
35. Pastushkova, L. Kh. *et al.* Changes of Protein Profile of Human Urine after Long-Term Orbital Flights. *Bull. Exp. Biol. Med.* **156**, 201–204 (2013).
36. View a PASSEL Dataset.
https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/PASS_View?identifier=PASS002
- 39.
37. Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *J. Proteome Res.* **18**, 623–632 (2019).
38. Szklarczyk, D. *et al.* The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**, D638–D646 (2023).
39. Mason, C. E. 39. Inspiration4 plasma metabolomics. (2023).
40. Uruno, A. *et al.* Nrf2 plays a critical role in the metabolic response during and after spaceflight. *Commun. Biol.* **4**, 1–18 (2021).

41. ibSLS - Metabolite List -. <https://ibsls.megabank.tohoku.ac.jp/metabolite-list>.
42. Zhang, H. *et al.* Serum Metabolomics Associating With Circulating MicroRNA Profiles Reveal the Role of miR-383-5p in Rat Hippocampus Under Simulated Microgravity. *Front. Physiol.* **11**, (2020).
43. Pang, Z. *et al.* MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. *Nucleic Acids Res.* **49**, W388–W396 (2021).
44. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-249>.
45. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-250>.
46. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-466>.
47. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-465>.
48. Jiang, P., Green, S. J., Chlipala, G. E., Turek, F. W. & Vitaterna, M. H. Reproducible changes in the gut microbiome suggest a shift in microbial and host metabolism during spaceflight. *Microbiome* **7**, 113 (2019).
49. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-212>.
50. Ritchie, L. E. *et al.* Space Environmental Factor Impacts upon Murine Colon Microbiota and Mucosal Homeostasis. *PLOS ONE* **10**, e0125792 (2015).
51. NASA OSDR: Open Science for Life in Space.
<https://osdr.nasa.gov/bio/repo/data/studies/OSD-72>.
52. Weber, N. *et al.* Nephele: a cloud platform for simplified, standardized and reproducible microbiome data analysis. *Bioinformatics* **34**, 1411–1413 (2018).
53. thomazbastiaanssen. 0. Introduction. (2023).

54. Bastiaanssen, T. F. S., Quinn, T. P. & Loughman, A. Bugs as Features (Part I): Concepts and Foundations for the Compositional Data Analysis of the Microbiome-Gut-Brain Axis. (2022) doi:10.48550/arXiv.2207.12475.
55. Inker, L. A. *et al.* New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *N. Engl. J. Med.* **385**, 1737–1749 (2021).
56. Topf, J. M. & Murray, P. T. Hypomagnesemia and Hypermagnesemia. *Rev. Endocr. Metab. Disord.* **4**, 195–206 (2003).
57. Coulthard, M. G. & Haycock, G. B. Distinguishing between salt poisoning and hypernatraemic dehydration in children. *BMJ* **326**, 157–160 (2003).
58. Stark, H., Eisenstein, B., Tieder, M., Rachmel, A. & Alpert, G. Direct Measurement of TP/GFR: A Simple and Reliable Parameter of Renal Phosphate Handling. *Nephron* **44**, 125–128 (2008).
59. Choi, M. J. & Ziyadeh, F. N. The Utility of the Transtubular Potassium Gradient in the Evaluation of Hyperkalemia. *J. Am. Soc. Nephrol.* **19**, 424–426 (2008).
60. Martín-Calderón, J. L. *et al.* Choice of the best equation for plasma osmolality calculation: Comparison of fourteen formulae. *Clin. Biochem.* **48**, 529–533 (2015).
61. Free water clearance. *Wikipedia* (2021).
62. The Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res.* **49**, D325–D334 (2021).
63. Crowdis, J., He, M. X., Reardon, B. & Van Allen, E. M. CoMut: visualizing integrated molecular information with comutation plots. *Bioinformatics* **36**, 4348–4349 (2020).
64. Morris, J. H. *et al.* The scalable precision medicine open knowledge engine (SPOKE): a massive knowledge graph of biomedical information. *Bioinformatics* **39**, btad080 (2023).
65. Berg, S. *et al.* ilastik: interactive machine learning for (bio)image analysis. *Nat. Methods* **16**, 1226–1232 (2019).
66. Park, Y.-G. *et al.* Protection of tissue physicochemical properties using polyfunctional crosslinkers. *Nat. Biotechnol.* **37**, 73–83 (2019).

67. Voigt, F. F. *et al.* The mesoSPIM initiative: open-source light-sheet microscopes for imaging cleared tissue. *Nat. Methods* **16**, 1105–1108 (2019).
68. Pidhorskyi, S., Morehead, M., Jones, Q., Spirou, G. & Doretto, G. syGlass: Interactive Exploration of Multidimensional Images Using Virtual Reality Head-mounted Displays. Preprint at <https://doi.org/10.48550/arXiv.1804.08197> (2018).
69. Imaris Microscopy Image Analysis Software | Comparison - Imaris. *Oxford Instruments* <https://imaris.oxinst.com/packages>.